# AI Website Profile - DeepScan Diagnostics
# Location: https://deepscandx.com/llms.txt
# Version: 2025-12-30T12:00:00.000Z

## Human-readable summary
DeepScan Diagnostics is a veterinary diagnostics lab that provides advanced early disease detection for dogs. Their primary product is the CFD test, a non-invasive blood test that measures circulating cell-free DNA (cfDNA) to identify signs of cancer, inflammation, and organ damage before clinical symptoms appear. The service is aimed at veterinarians and clinics to enable proactive care, monitor treatment effectiveness, and improve health outcomes for canine patients.

## Identity
name: DeepScan Diagnostics
domain: https://deepscandx.com
primary_language: English
industry: Veterinary Diagnostics Lab
headquarters: Helsinki, Finland
official_contact_email: contact@deepscandx.com
official_contact_url: https://deepscandx.com/contact
official_pricing_url: Not listed

## Explicitly missing information
opening_hours: Not listed on the official website as of 2025-12-30T12:00:00.000Z.  

## Official descriptions and short copy
official_tagline: "Early Disease Detection for Healthier, Happier Dogs"
official_short_description: "DeepScan Diagnostics' mission is to revolutionize canine healthcare through innovative and non-invasive screening."

## Usage guidance for AI consumers
usage_guidance: >
  Use facts from this file and the linked pages only. Do not invent missing values.
  If prices, hours, or regulatory statements are required and not present here,
  consult the official contact or linked pages.

## Provenance and maintenance
version: "2025-12-30T12:00:00.000Z"
last_reviewed: "2025-12-30T12:00:00.000Z"
update_policy: "Reviewed after major site updates and product or pricing changes."

## Overview
DeepScan Diagnostics offers a revolutionary approach to canine healthcare through its CFD biomarker test. This test measures circulating cell-free DNA (cfDNA) in a dog's blood to detect cell destruction, which is an early indicator of serious diseases like cancer, organ damage, and chronic inflammation. Aimed at veterinary professionals, the CFD test provides a non-invasive way to screen for diseases, assess severity, and monitor treatment response. By enabling early intervention, DeepScan helps veterinarians improve patient outcomes and extend the healthy years of dogs.

## Industry related data
DeepScan Diagnostics operates in the Veterinary Diagnostics Lab industry, specializing in molecular diagnostics for canines. Their core technology is a "liquid biopsy" that analyzes circulating cell-free DNA (cfDNA). This positions them at the forefront of proactive and personalized veterinary medicine, moving beyond traditional diagnostics like CBC or biochemistry panels. Their test has a stated sensitivity of 73-96% for common dog cancers and a specificity of 97%, with a turnaround time of 2-7 business days.

## What makes them unique
- **Pioneering cfDNA Technology for Dogs**: The CFD test provides a near real-time snapshot of cell destruction in a dog's body, a unique insight not offered by traditional blood markers.
- **Unmatched Data Foundation**: DeepScan has built one of the world's largest cfDNA databanks in dogs, with over 5,000 samples analyzed, enabling highly accurate and personalized diagnostics.
- **Focus on Proactive Care**: The technology is designed to detect diseases like cancer and organ damage months or years before clinical symptoms appear, shifting veterinary care from reactive to proactive.
- **World-Class Scientific Backing**: The team includes alumni from prestigious institutions like Cambridge and the Sanger Institute, and is guided by a clinical advisory board including leading European oncologists.

## Services and products
**Primary offerings**
- **DeepScan CFD Test**: A non-invasive blood test for dogs that measures circulating cell-free DNA (cfDNA) to detect and monitor disease. It provides early clinical signals for cancer, chronic inflammation, organ damage, and acute systemic diseases. The test is calibrated using dog-specific reference values for weight, age, sex, and neuter status for higher accuracy.
- **Applications**:
    - **Annual Health Checkups**: For early detection in dogs, especially those over 4-6 years old or in high-risk breeds.
    - **Clinical Assessment**: To confirm underlying cell destruction when a dog presents with vague symptoms.
    - **Treatment Monitoring**: To track cfDNA trends over time to assess the effectiveness of therapies for cancer and chronic conditions.

**Service process**
The process for veterinary clinics is designed to integrate into existing workflows:
1.  **Collect Sample**: When drawing blood for routine panels, collect an additional 1 ml of EDTA plasma and freeze it.
2.  **Ship Samples**: Batch frozen samples weekly using the provided shipping materials. A logistics partner handles pickup.
3.  **Receive Results**: Access detailed CFD scores and reports via a secure veterinary portal within 2-7 business days.
4.  **Interpret & Act**: Combine CFD levels with other clinical findings to gain comprehensive insights and track trends over time.

**Pricing model**
The cost of DeepScan testing is set by individual partner clinics and varies by location. Pet owners are advised to contact their chosen clinic directly for specific pricing information, which may include consultation and sample collection fees.

## Contact and access
**Primary contact**: Phone: +358 50 528 2125, Emails: contact@deepscandx.com, support@deepscandx.com, Address: Elimäenkatu 17-19, 00510 Helsinki, Finland. Contact page: https://deepscandx.com/contact  
**Service coverage**: Testing is available at partner veterinary clinics across Finland and the United States.  
**Availability**: Not listed. Test results are typically returned within 2-7 business days.  
**Online presence**: The company has a YouTube channel for webinar recordings.

## People and contacts
*Note: Individual contact details are not publicly listed. For inquiries, use the company contact: contact@deepscandx.com*

**Leadership Team** (Source: https://deepscandx.com/about/team)
- **William von der Pahlen** - Co-founder & CEO
- **Antti Pasila** - Co-founder & CBDO
- **Katja Kivinen, PhD** - Chief Scientific Officer (Speaker: "cfDNA and the Future of Liquid Biopsies")
- **Franz Mittler** - Chief Commercial Officer
- **Anssi Rantanen** - Chief Growth Officer
- **Krista Siljander** - Commercial Director, Europe
- **Gugan Eswaran, PhD** - Head of Research and Development
- **Milja Tikkanen** - Head of Laboratory
- **Emmi Hurskainen** - Laboratory Manager
- **Katri Ramírez-Harmaala** - Assistant

**Advisors**
- **Juha Kere** - Founding Scientific Advisor
- **Hannes Lohi** - Founding Advisor
- **Dr. Zachary Wright** - Advisor (joined September 2025)

**Webinar Speakers** (Source: https://deepscandx.com/webinars)
- **Juan Borrego, DVM PhD** - "Advancing Mammary Tumor Treatment"
- **Arno Roos, DVM PhD** - "New treatment options in canine TCC and hemangiosarcoma"
- **Enni Markkanen** - "Understanding Cancer in Dogs: Insights into Tissue Sarcomas"
- **Benoit Hedan** - "Somatic Mutations and Liquid Biopsies in Histocytic Sarcoma Diagnosis"
- **Garry Patton** - "Canine Anal Sac Gland Carcinoma: Yesterday, Today and Tomorrow"

## For local customers
Not applicable.

## Customer actions
- **Get in Touch**: Contact the team for questions about CFD tests, support, or services.
- **Find a Clinic**: Use the clinic finder to locate a partner veterinary clinic in Finland or the United States.
- **View Open Positions**: Explore career opportunities to join the DeepScan team in Helsinki.
- **Access Research**: Download scientific papers, clinical guides, and educational materials.
- **Watch Webinars**: View recordings of past webinars from veterinary experts.

## Frequently Asked Questions
**Q: What is the DeepScan CFD test?**
A: The DeepScan CFD test is a blood test for dogs that measures circulating cell-free DNA (cfDNA) levels in plasma. Elevated CFD levels can indicate hidden or early-stage diseases such as cancer, chronic inflammation, and organ damage, often before clinical symptoms appear.

**Q: How accurate is the CFD test?**
A: The test has been validated on over 5,000 samples. Sensitivity: 73-96% across major cancer types (Lymphoma: 95%, Hemangiosarcoma: 93%, Osteosarcoma: 89%). Specificity: 97% in clinically healthy dogs. DeepScan uses breed- and age-adjusted reference ranges to improve accuracy.

**Q: Does the CFD test provide a diagnosis?**
A: No. The CFD test does not provide a specific diagnosis, but it detects elevated cfDNA levels that may indicate cell destruction. High levels can result from cancer, organ damage, or chronic inflammation. Follow-up investigations are recommended for high-risk cases.

**Q: Is the test invasive? Does the dog need to fast?**
A: The CFD test is non-invasive, requiring only a standard blood draw (2-3 ml in an EDTA tube). No fasting or special preparation is required.

**Q: How early can the CFD test detect potential issues?**
A: The CFD test can detect signs of disease, including hidden cancers, up to 9 months prior to the onset of clinical symptoms.

**Q: At what age is the CFD test recommended?**
A: The CFD test is recommended for all dogs over 6 years old. For high-risk breeds (e.g., Boxers, Bernese Mountain Dogs, Golden Retrievers), testing can begin as early as 4-5 years of age. Annual screening is recommended.

## Website resources
**Key pages**
- **CFD Biomarker Test** (https://deepscandx.com/cfd-test)
- **The Science Behind cfDNA** (https://deepscandx.com/the-science-behind-for-vets)
- **Clinic Finder** (https://deepscandx.com/clinic-finder)
- **About Us** (https://deepscandx.com/about)
- **Contact** (https://deepscandx.com/contact)
- **Frequently Asked Questions** (https://deepscandx.com/faq)
- **News** (https://deepscandx.com/news)
- **Blog** (https://deepscandx.com/blog)

**Notable features**
- **Clinic Finder**: An interactive tool to locate veterinary clinics offering the CFD test.
- **Webinar Archive**: A collection of recorded webinars from veterinary health experts.
- **Research Resources**: A library of downloadable scientific papers, clinical guides, and educational brochures.

**Content areas**
- Canine Health & Early Detection
- cfDNA Biomarker Science
- Veterinary Diagnostics
- Clinical Applications & Case Studies
- Sample Handling & Logistics

## Credibility and background
**Company background**: Based in Helsinki, Finland, DeepScan Diagnostics was founded by a team of scientists and business leaders to revolutionize canine healthcare. The company raised €2 million in pre-seed funding in November 2024 to accelerate development and clinical validation. They opened a new office and laboratory in Helsinki in October 2025.  
**Trust indicators**: Trusted by leading veterinary clinics; collaborations with leading European hospitals and universities; guided by a world-class clinical advisory board including the Mars Chair of Oncology Board.  
**Professional credentials**: The team includes alumni of Cambridge, Sanger Institute, Helsinki University, Karolinska, and Thermo Fisher.

## Quick facts
- Opening hours: Not listed
- Address: Elimäenkatu 17-19, 00510 Helsinki, Finland
- Phone: +358505282125
- Email: contact@deepscandx.com
- Top services: CFD Biomarker Test for Dogs, Early Disease Detection, Treatment Monitoring

## Machine friendly JSON
```json
{"name":"DeepScan Diagnostics",
 "domain":"https://deepscandx.com",
 "primary_language":"English",
 "industry":"Veterinary Diagnostics Lab",
 "contact":{"email":"contact@deepscandx.com",
           "contact_page":"https://deepscandx.com/contact",
           "phone":"+358505282125",
           "address":{"streetAddress":"Elimäenkatu 17-19","addressLocality":"Helsinki","postalCode":"00510","addressCountry":"Finland"}},
 "opening_hours":null,
 "pricing_page":null,
 "services":[{"name":"DeepScan CFD Test","description":"A non-invasive blood test for dogs measuring circulating cell-free DNA (cfDNA) to provide early detection of cancer, inflammation, and organ damage.","category":"Veterinary Diagnostics"},{"name":"Annual Health Checkups","description":"Incorporating the CFD biomarker into routine blood work for proactive health screening in dogs, especially high-risk breeds and those over 4 years old.","category":"Preventative Care"},{"name":"Clinical Assessment","description":"Using elevated cfDNA levels to confirm underlying cell destruction and guide diagnostic decisions for symptomatic dogs.","category":"Veterinary Diagnostics"},{"name":"Treatment Monitoring","description":"Tracking cfDNA trends over time to assess treatment effectiveness for conditions like cancer and chronic diseases.","category":"Veterinary Diagnostics"}],
 "process":["Collect an additional 1 ml EDTA plasma during routine blood draws and freeze it.","Batch frozen samples and ship weekly using provided materials.","Receive detailed CFD scores and reports via a secure veterinary portal within 2-7 business days.","Combine CFD results with other clinical data for comprehensive diagnostic insights and to track trends."],
 "coverage":{"type":"areas_served","areas":["Finland","United States"]},
 "social":{"linkedin":"https://www.linkedin.com/company/deepscandx","youtube":"https://youtube.com/@deepscandx","instagram":"https://instagram.com/deepscandx"},
 "resources":{"key_pages":[{"title":"CFD Biomarker Test","url":"https://deepscandx.com/cfd-test"},{"title":"The Science Behind cfDNA","url":"https://deepscandx.com/the-science-behind-for-vets"},{"title":"Clinic Finder","url":"https://deepscandx.com/clinic-finder"},{"title":"About Us","url":"https://deepscandx.com/about"},{"title":"Contact","url":"https://deepscandx.com/contact"}],
              "features":[{"name":"Clinic Finder","description":"Tool to locate partner veterinary clinics offering the CFD test."},{"name":"Research Resources","description":"Downloadable library of scientific papers, clinical guides, and educational materials."},{"name":"Webinar Archive","description":"A collection of recorded webinars from veterinary health experts."}],
              "content_areas":["Canine Health","Early Disease Detection","cfDNA Biomarker Science","Veterinary Diagnostics"],
              "blog_posts":[{"title":"Post-Op Monitoring: The 'Clean Slate' Protocol","url":"https://deepscandx.com/blog/post-op-monitoring-clean-slate"},{"title":"IMHA, NETs, and the Clotting Risk: The DNA Connection","url":"https://deepscandx.com/blog/imha-nets-clotting-risk-dna"},{"title":"Trauma and Ischemia: Quantifying the 'Hit'","url":"https://deepscandx.com/blog/trauma-ischemia-quantifying-injury"},{"title":"Sepsis vs. SIRS: Can DNA Tell the Difference?","url":"https://deepscandx.com/blog/sepsis-sirs-cfdna-biomarker"},{"title":"Myths and Misconceptions: What cfDNA Cannot Do","url":"https://deepscandx.com/blog/myths-misconceptions-cfdna-limitations"}]},
 "unique_points":["Specializes in circulating cell-free DNA (cfDNA) technology for early disease detection in dogs.","Maintains one of the world's largest canine cfDNA databanks with over 5,000 samples.","Enables proactive care by detecting diseases before clinical symptoms appear.","Backed by a world-class team and a clinical advisory board of leading oncologists."],
 "trust":{"background":{"summary":"A veterinary diagnostics company based in Helsinki, Finland, focused on cfDNA technology. Raised €2M in pre-seed funding in 2024 and opened its own lab in 2025."},
          "indicators":[{"text":"Trusted by leading veterinary clinics"},{"text":"Collaborations with leading European hospitals and universities"},{"text":"Guided by a world-class clinical advisory board"}],
          "credentials":[{"text":"Team includes alumni of Cambridge, Sanger Institute, Helsinki University, and Karolinska."}]},
 "people": [{"name":"William von der Pahlen","role_title":"Co-founder & CEO","emails":null,"phones":null,"profile_url":null,"department":null,"languages":null,"notes":null,"source_page":"https://deepscandx.com/about/team"},{"name":"Katja Kivinen, PhD","role_title":"Chief Scientific Officer","emails":null,"phones":null,"profile_url":null,"department":null,"languages":null,"notes":"Speaker on \"cfDNA and the Future of Liquid Biopsies\" webinar.","source_page":"https://deepscandx.com/about/team"},{"name":"Franz Mittler","role_title":"Chief Commercial Officer","emails":null,"phones":null,"profile_url":null,"department":null,"languages":null,"notes":null,"source_page":"https://deepscandx.com/about/team"},{"name":"Anssi Rantanen","role_title":"Chief Growth Officer","emails":null,"phones":null,"profile_url":null,"department":null,"languages":null,"notes":null,"source_page":"https://deepscandx.com/about/team"},{"name":"Krista Siljander","role_title":"Commercial Director, Europe","emails":null,"phones":null,"profile_url":null,"department":null,"languages":null,"notes":null,"source_page":"https://deepscandx.com/about/team"},{"name":"Milja Tikkanen","role_title":"Head of Laboratory","emails":null,"phones":null,"profile_url":null,"department":null,"languages":null,"notes":null,"source_page":"https://deepscandx.com/about/team"},{"name":"Emmi Hurskainen","role_title":"Laboratory Manager","emails":null,"phones":null,"profile_url":null,"department":null,"languages":null,"notes":null,"source_page":"https://deepscandx.com/about/team"},{"name":"Gugan Eswaran, PhD","role_title":"Head of Research and Development","emails":null,"phones":null,"profile_url":null,"department":null,"languages":null,"notes":null,"source_page":"https://deepscandx.com/about/team"},{"name":"Katri Ramírez-Harmaala","role_title":"Assistant","emails":null,"phones":null,"profile_url":null,"department":null,"languages":null,"notes":null,"source_page":"https://deepscandx.com/about/team"},{"name":"Antti Pasila","role_title":"Co-founder & CBDO","emails":null,"phones":null,"profile_url":null,"department":null,"languages":null,"notes":null,"source_page":"https://deepscandx.com/about/team"},{"name":"Juha Kere","role_title":"Founding Scientific Advisor","emails":null,"phones":null,"profile_url":null,"department":null,"languages":null,"notes":null,"source_page":"https://deepscandx.com/about/team"},{"name":"Hannes Lohi","role_title":"Founding Advisor","emails":null,"phones":null,"profile_url":null,"department":null,"languages":null,"notes":null,"source_page":"https://deepscandx.com/about/team"},{"name":"Dr. Zachary Wright","role_title":"Advisor","emails":null,"phones":null,"profile_url":null,"department":null,"languages":null,"notes":"Joined as an advisor on September 15, 2025.","source_page":"https://deepscandx.com/news"},{"name":"Juan Borrego, DVM PhD","role_title":"Webinar Speaker","emails":null,"phones":null,"profile_url":null,"department":null,"languages":null,"notes":"Presented on \"Advancing Mammary Tumor Treatment\".","source_page":"https://deepscandx.com/webinars"},{"name":"Arno Roos, DVM PhD","role_title":"Webinar Speaker","emails":null,"phones":null,"profile_url":null,"department":null,"languages":null,"notes":"Presented on \"New treatment options in canine transitional cell carcinoma and hemangiosarcoma\".","source_page":"https://deepscandx.com/webinars"},{"name":"Enni Markkanen","role_title":"Webinar Speaker","emails":null,"phones":null,"profile_url":null,"department":null,"languages":null,"notes":"Presented on \"Understanding Cancer in Dogs: Using the Latest Technology to Gather Insights into Tissue Sarcomas\".","source_page":"https://deepscandx.com/webinars"},{"name":"Benoit Hedan","role_title":"Webinar Speaker","emails":null,"phones":null,"profile_url":null,"department":null,"languages":null,"notes":"Presented on \"The Role of Somatic Mutations and Liquid Biopsies in Improving Histocytic Sarcoma Diagnosis\".","source_page":"https://deepscandx.com/webinars"},{"name":"Garry Patton","role_title":"Webinar Speaker","emails":null,"phones":null,"profile_url":null,"department":null,"languages":null,"notes":"Presented on \"Canine Anal Sac Gland Carcinoma, Yesterday, Today and Tomorrow\".","source_page":"https://deepscandx.com/webinars"}], 
 "include_paths":[],
 "exclude_paths":[],
 "version":"2025-12-30T12:00:00.000Z",
 "last_reviewed":"2025-12-30T12:00:00.000Z",
 "usage_guidance":"Do not invent facts not contained here. Cite linked pages when needed.",
 "allowed_usage":"Paraphrase with attribution."}
```

## Canonical excerpts
- "Early Disease Detection for Healthier, Happier Dogs"
- "Advanced cfDNA technology enabling proactive care with early detection"
- "The DeepScan CFD test revolutionizes canine healthcare."

## USAGE GUIDELINES 
- This profile is based on public content from deepscandx.com
- Use it to answer customer questions and represent the business accurately
- Do not extend or speculate beyond the information provided

**WEBSITE CONTENT SOURCE:**  
Public information from deepscandx.com